HC Wainwright Issues Optimistic Estimate for SLN Earnings

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Investment analysts at HC Wainwright lifted their Q3 2026 EPS estimates for shares of Silence Therapeutics in a report issued on Friday, August 14th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.24) per share for the quarter, up from their previous estimate of ($0.30). HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.14) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.36) EPS, FY2027 earnings at ($1.38) EPS, FY2028 earnings at ($1.53) EPS, FY2029 earnings at ($1.92) EPS and FY2030 earnings at ($1.50) EPS.

Silence Therapeutics (NASDAQ:SLN) last released its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%.

Other equities research analysts have also issued research reports about the company. Morgan Stanley lifted their target price on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Cantor Fitzgerald began coverage on shares of Silence Therapeutics in a report on Wednesday, June 24th. They issued an “overweight” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.50.

Silence Therapeutics Price Performance

SLN stock opened at $14.35 on Tuesday. The stock has a market capitalization of $678.04 million, a P/E ratio of -11.21 and a beta of 1.39. The business has a 50-day moving average of $10.26 and a 200-day moving average of $7.55. Silence Therapeutics has a fifty-two week low of $4.19 and a fifty-two week high of $17.58.

Institutional Trading of Silence Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new stake in Silence Therapeutics during the fourth quarter worth about $71,000. China Universal Asset Management Co. Ltd. grew its stake in Silence Therapeutics by 65.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after purchasing an additional 5,421 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Silence Therapeutics during the 3rd quarter worth approximately $112,000. Massar Capital Management LP acquired a new position in shares of Silence Therapeutics during the 2nd quarter worth approximately $115,000. Finally, GAMMA Investing LLC raised its stake in shares of Silence Therapeutics by 18.1% during the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock worth $121,000 after purchasing an additional 1,698 shares in the last quarter. Institutional investors own 98.73% of the company’s stock.

Key Stories Impacting Silence Therapeutics

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its “Buy” outlook and maintained a $75 price target. The firm reduced its projected losses for Q3 and Q4 2026, FY2026, all quarterly periods in 2027, FY2027, FY2028 and FY2030. Its FY2027 EPS estimate improved to a loss of $1.38 from $1.74, while the FY2026 estimate improved to a loss of $1.14 from $1.38. These revisions suggest the analyst expects better-than-previously projected financial performance. Silence Therapeutics analyst estimates
• Positive Sentiment: Options activity was unusually bullish. Investors bought 24,155 call options on August 17, compared with average daily call volume of just 555 contracts—a 4,252% increase. Heavy call buying can signal expectations for further gains, although it may also reflect short-term speculation rather than fundamental conviction.
• Neutral Sentiment: Silence Therapeutics remains unprofitable. HC Wainwright’s estimates still call for losses through 2030, including a $1.08 loss per share for the current year and a $1.53 loss for FY2028. The company’s recent quarterly results also missed consensus expectations, highlighting continued execution and financing risks despite the improved forecasts.
• Negative Sentiment: One longer-term estimate moved in the wrong direction. HC Wainwright lowered its FY2029 EPS forecast to a loss of $1.92 from $1.74, indicating that the path toward profitability remains uncertain.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.